PMID- 32326261
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2226-4787 (Electronic)
IS  - 2226-4787 (Linking)
VI  - 8
IP  - 2
DP  - 2020 Apr 21
TI  - Glycopeptide Hypersensitivity and Adverse Reactions.
LID - 10.3390/pharmacy8020070 [doi]
LID - 70
AB  - Glycopeptides, such as vancomycin and teicoplanin, are primarily used in the 
      treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections, such 
      as cellulitis, endocarditis, meningitis, pneumonia, and septicemia, and are some 
      of the most commonly prescribed parenteral antimicrobials. Parenteral 
      glycopeptides are first-line therapy for severe MRSA infections; however, oral 
      vancomycin is used as a first-line treatment of Clostridioides difficile 
      infections. Also, we currently have the longer-acting lipoglycopeptides, such as 
      dalbavancin, oritavancin, and telavancin to our armamentarium for the treatment 
      of MRSA infections. Lastly, vancomycin is often used as an alternative treatment 
      for patients with beta-lactam hypersensitivity. Common adverse effects associated 
      with glycopeptide use include nephrotoxicity, ototoxicity, and Redman Syndrome 
      (RMS). The RMS is often mistaken for a true allergy; however, it is a 
      histamine-related infusion reaction rather than a true immunoglobulin E 
      (IgE)-mediated allergic reaction. Although hypersensitivity to glycopeptides is 
      rare, both immune-mediated and delayed reactions have been reported in the 
      literature. We describe the various types of glycopeptide hypersensitivity 
      reactions associated with glycopeptides and lipoglycopeptides, including 
      IgE-mediated reactions, RMS, and linear immunoglobulin A bullous dermatosis, as 
      well as describe cross-reactivity with other glycopeptides.
FAU - Huang, Vanthida
AU  - Huang V
AD  - Department of Pharmacy Practice, Midwestern University College of 
      Pharmacy-Glendale, Glendale, AZ 85308, USA.
FAU - Clayton, Nicola A
AU  - Clayton NA
AD  - Department of Pharmacy Services, UC Davis Health, Sacramento, CA 95817, USA.
FAU - Welker, Kimberly H
AU  - Welker KH
AD  - Department of Pharmacy Services, Mercy Gilbert Medical Center, Dignity Health, 
      Gilbert, AZ 85297, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200421
PL  - Switzerland
TA  - Pharmacy (Basel)
JT  - Pharmacy (Basel, Switzerland)
JID - 101678532
PMC - PMC7357119
OTO - NOTNLM
OT  - Redman Syndrome
OT  - dalbavancin
OT  - glycopeptides
OT  - hypersensitivity
OT  - lipoglycopeptides
OT  - oritavancin
OT  - teicoplanin
OT  - telavancin
OT  - vancomycin
COIS- The authors declare no conflict of interest.
EDAT- 2020/04/25 06:00
MHDA- 2020/04/25 06:01
PMCR- 2020/04/21
CRDT- 2020/04/25 06:00
PHST- 2020/01/05 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/04/18 00:00 [accepted]
PHST- 2020/04/25 06:00 [entrez]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2020/04/25 06:01 [medline]
PHST- 2020/04/21 00:00 [pmc-release]
AID - pharmacy8020070 [pii]
AID - pharmacy-08-00070 [pii]
AID - 10.3390/pharmacy8020070 [doi]
PST - epublish
SO  - Pharmacy (Basel). 2020 Apr 21;8(2):70. doi: 10.3390/pharmacy8020070.